[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer; 2006 Apr 15;106(8):1776-84
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
  • BACKGROUND: Extensive and mutilating surgery is often required for locally advanced soft tissue sarcoma (STS) of the limb.
  • ILPs were performed at mild hyperthermic conditions with 1-4 mg of TNF and 10-13 mg/L limb-volume melphalan (M) for leg and arm perfusions, respectively.
  • The procedure could be performed safely, with a perioperative mortality of 0.5% in all patients with no age limit (median age, 54 yrs; range, 12-91).
  • CONCLUSION: TNF+M-based ILP can provide limb salvage in a significant percentage of patients with locally advanced STS and has therefore gained a permanent place in the multimodality treatment of STS.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Extremities. Limb Salvage. Melphalan / administration & dosage. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prognosis. Recombinant Proteins / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16541435.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


2. van Ginkel RJ, Thijssens KM, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ: Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol; 2007 Apr;14(4):1499-506
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
  • BACKGROUND: The aim of this study was to investigate the long-term limb salvage rate and overall survival after isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma (STS).
  • We found that the risk of amputation was linked to three time periods.
  • The first was within a year after perfusion, mainly as a result of massive necrosis of the tumor and overlying skin, resulting in soft tissue deficit or recurrent disease (n = 17).
  • The third occurred 10 years after perfusion, with two amputations performed for critical leg ischemia.
  • Another two patients developed a pathological fracture of the femur due to radiation osteonecrosis.
  • CONCLUSIONS: ILP treatment with tumor necrosis factor alpha and melphalan followed by delayed surgical resection and adjuvant radiation treatment is an effective limb salvage treatment regimen for locally advanced STS.
  • However, we observed late morbidity, with two amputations performed for critical leg ischemia and two pathological fractures of the femur in patients receiving adjuvant radiotherapy.
  • [MeSH-major] Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Risk Factors. Survival Rate. Tumor Necrosis Factor-alpha / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):745-50 [11020571.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):616-21 [2743257.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):792-7 [11087648.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):355-63 [11986187.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Radiology. 1971 Nov;101(2):429-33 [5114783.001]
  • [Cites] Br J Radiol. 1974 Feb;47(554):157-8 [4817460.001]
  • [Cites] Radiat Res. 1975 Jul;63(1):157-64 [1144676.001]
  • [Cites] Ann Surg. 1977 May;185(5):555-64 [266397.001]
  • [Cites] Ann Surg. 1980;192(4):431-8 [6932827.001]
  • [Cites] Cancer. 1981 May 1;47(9):2269-74 [7226121.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Am J Surg. 1988 May;155(5):667-71 [3369621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):52-60 [1727926.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2140-6 [8156518.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):43-7 [7802575.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):382-8 [7850539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1289-300 [7635768.001]
  • [Cites] Arch Surg. 1996 Jun;131(6):672-4 [8645079.001]
  • [Cites] Crit Care Med. 1996 May;24(5):765-70 [8706451.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):528-31 [8903498.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 [8968230.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1129-37 [9070490.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jul;(352):168-78 [9678045.001]
  • [Cites] Cancer Treat Rev. 1998 Dec;24(6):373-91 [10189405.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):669-78 [11078614.001]
  • (PMID = 17253101.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1914273
  •  go-up   go-down


3. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • Isolated limb perfusion (ILP) has proven to be an excellent, local, limb-saving treatment option in patients with locally advanced extremity tumors.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • Limb salvage was achieved in 36 of 37 patients, with 1 patient undergoing amputation due to treatment toxicity.
  • CONCLUSIONS: TNF-based ILP is an excellent procedure that provided tumor control and limb salvage for the short survival of patients with metastasized, very bulky, limb-threatening tumors of the extremity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


Advertisement
4. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Siebenrock KA, Hertel R, Ganz R: Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery. Arch Orthop Trauma Surg; 2000;120(1-2):65-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unexpected resection of soft-tissue sarcoma. More mutilating surgery, higher local recurrence rates, and obscure prognosis as consequences of improper surgery.
  • Sixteen referred patients were reviewed after excision of an unexpected soft-tissue sarcoma of the extremities.
  • Four patients received adjuvant local radiation, with additional chemotherapy in 2 of them.
  • At an average follow-up of 4.5 years (range 15-149 months), 4 patients (25%) had developed distant metastases with a local recurrence in 3 (19%).
  • Evaluation by adequate imaging techniques, biopsy, and definitive resection and reconstruction should be performed by an oncologically trained orthopaedic surgeon.
  • [MeSH-major] Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation. Chemotherapy, Adjuvant. Female. Forearm. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Reoperation. Shoulder

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653107.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


6. Zawitkowska-Klaczyńska J, Katski K, Woźniak M, Kowalczyk JR: Characteristics and outcome of children with primary soft tissue sarcomas of extremities. Med Wieku Rozwoj; 2004 Apr-Jun;8(2 Pt 1):169-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of children with primary soft tissue sarcomas of extremities.
  • OBJECTIVES: To determine the characteristics and outcome or patients with primary soft tissue sarcomas of extremities in children.
  • MATERIAL AND METHODS: Thirty-six patients treated for soft tissues sarcomas were enrolled into the study.
  • Features analysed: the incidence of soft tissues sarcoma of extremities, the time from first clinical symptoms to making the diagnosis, the primary site of tumour; histopathologic type of tumour, stage of disease, methods and results of the treatment.
  • RESULTS: The time From first symptoms to making the diagnosis was 5.4 months (mean).
  • Histopathologic types: synovial sarcoma in 4 patients, malignant haemangiopericytoma in 2, rhabdomyosarcoma in 2, sarcoma myogenes in 1, primitive neuroectodermal tumour in l.
  • Patients underwent treatment according to the soft tissue sarcoma protocols.
  • Results of treatment: first complete remission was observed in 7 patients; second complete remission in 1, one patient is on postoperative treatment.
  • Combined treatment achieves full remission in the majority of patients with soft tissues sarcomas localized within the limbs.
  • 2. In patients with large tumours (>5 cm) the treatment should to be started with inductive chemotherapy, and the surgery should be postponed.
  • 3. Early excision of the tumour should be considered in cases of small tumours (< 5 cm), when resection with wide margin of healthy tissues is possible, without deteriorating the function of the limb or cosmetic damage.
  • [MeSH-major] Arm. Leg. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiopericytoma / diagnosis. Hemangiopericytoma / therapy. Humans. Incidence. Male. Myosarcoma / diagnosis. Myosarcoma / therapy. Neoplasm Staging. Neuroectodermal Tumors / diagnosis. Neuroectodermal Tumors / therapy. Poland / epidemiology. Retrospective Studies. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy. Survival Analysis. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15738590.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


7. Picci P: Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults. Curr Oncol Rep; 2000 Nov;2(6):502-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for extremity soft-tissue sarcomas in adults.
  • Due to the peculiar characteristics of sarcomas, which include classification problems, heterogeneity of presentation, and treatment, no consensus exists regarding the best strategies to follow.
  • In particular, there is no consensus on the use of chemotherapy in localized high-grade sarcomas, with contradictory results reported in medical literature.
  • Both studies confirm the advantage of adjuvant chemotherapy in disease-free and overall surivall in very select groups of high-grade sarcomas of the extremities.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Arm / pathology. Arm / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Leg / pathology. Leg / surgery. Neoplasm Staging. Patient Selection. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):32-7 [9917750.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):57-69 [10030416.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):352-9 [10516382.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1438-43 [9552049.001]
  • [Cites] Acta Orthop Scand Suppl. 1999 Jun;285:50-7 [10429623.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1418-26 [9193334.001]
  • [Cites] J Clin Oncol. 1986 Apr;4(4):552-8 [3514804.001]
  • [Cites] Oncology. 1999;56(1):13-23 [9885372.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2772-80 [10561352.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):328-48 [10516380.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):349-51 [10516381.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Sep-Oct;16(5):397-406 [10505315.001]
  • [Cites] Arch Surg. 1999 Aug;134(8):856-61; discussion 861-2 [10443809.001]
  • [Cites] J Surg Oncol. 1999 Jul;71(3):155-61 [10404131.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1219 [10561182.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):15-21 [8418226.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1121-34 [8203453.001]
  • [Cites] Semin Surg Oncol. 1999 Jul-Aug;17(1):47-51 [10402637.001]
  • (PMID = 11122885.001).
  • [ISSN] 1523-3790
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


8. Adam Z, Veselý K, Krejcí M, Pour L, Fakan F, Soumarová R, Neubauer J, Vanícek J, Cerný J, Kren L, Bolcák K, Smardová L, Hájek R, Mayer J: [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation]. Vnitr Lek; 2009 Feb;55(2):147-57
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
  • Interdigitating dendritic cell sarcoma is a rare neoplasm forming part of the group of malignancies derived from histocytic cell line.
  • The pathological process affected proximal tibial epiphysis and adjacent soft tissues.
  • Histological examination of a diagnostic excision specimen of the tumour in the tibia and the extirpated enlarged regional nodes in the left groin led to the diagnosis of interdigitating dendritic cell sarcoma.
  • The diagnosis was confirmed pathologically by another two centres in the Czech Republic and, due to the unusual nature of the diagnosis, also in Regensburg, Germany.
  • Treatment started with chemotherapy, applied to patients with aggressive lymphomas in the framework of clinical studies, i.e. a combination of MegaCHOP.
  • MegaCHOP therapy was therefore discontinued after the 4 cycles.
  • Subsequently, we referred the patient for a high-dose chemotherapy with autologous bone marrow transplantation, similarly to aggressive lymphomas.
  • The collection of blood producing stem cells from peripheral blood was successfully performed after ESHAP chemotherapy.
  • A verificatoin FDG-PET examination was performed before high-dose chemotherapy.
  • One month after ESHAP chemotherapy, BEAM high-dose chemotherapy with autologous transplantation of blood forming tissue was performed.
  • High-dose chemotherapy was followed up by radiotherapy targeted on the primary tumour in the crus (70 Gy).
  • The activity corresponded to the presence of viable tumour tissue in the primary nidus and new metastases in inguinal nodes, without proofs of further proliferation at the time.
  • Histological examination showed affection of the node by the same type of tumour, i.e. a continuing activity of the disease despite chemotherapy.
  • Due to suspected continuation of viable tumour in the crus judging by the intensity of accumulation of FDG-PET and the proof of a new affection of regional nodes, surgical treatment was preferred after the failure of chemotherapy.
  • This was followed by regional inguinal node region radiotherapy (56 Gy).
  • The last fourth PET-CT examination carried out 4 months after the radiation therapy of the inguinal region showed massive dissemination into the region ofileac and paraaortic nodes (lymphadenopathy up to 6 cm in diameter) with an activity of 5.9 to 6.73 SUV units.
  • Currently, we test the sensitiveness of the disease to 2-chlordeoxyadenosin and look for additional therapeutic options.
  • To our knowledge, the above description is the first documented case of interdigitating dendritic cell sarcoma located in the tibia and crus soft tissue.
  • We have not found any description of high-dose therapy supported by autologous transplantation of blood-forming tissue for this type of tumour in relevant literature.
  • In this case, we record chemoresistance to high-dose chemotherapy and certain radiosensitivty of the tumour at the same time.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Dendritic Cell Sarcoma, Interdigitating / therapy. Drug Resistance, Neoplasm. Leg. Peripheral Blood Stem Cell Transplantation. Soft Tissue Neoplasms / therapy. Tibia
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Male. Melphalan / administration & dosage. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348397.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  • [Number-of-references] 69
  •  go-up   go-down


9. Rüdiger HA, Beltrami G, Campanacci DA, Mela MM, Franchi A, Capanna R: Soft tissue sarcomas of the popliteal fossa: outcome and risk factors. Eur J Surg Oncol; 2007 May;33(4):512-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcomas of the popliteal fossa: outcome and risk factors.
  • BACKGROUND: Limb salvage surgery of popliteal soft tissue sarcomas may be hampered due to the incomplete anatomical containment of this region and the vicinity of neurovascular structures.
  • PATIENTS AND METHODS: 27 patients (53.3+/-15.8 y; 16/27 male) with popliteal soft tissue sarcomas were assessed.
  • 9/27 patients were included after prior treatment elsewhere (5 after intralesional resections and 4 local recurrences).
  • 15/27 patients were subjected to radiation therapy (preoperative in 6/15 cases), 8/27 patients received chemotherapy (5/8 preoperatively).
  • 8/27 patients developed metastatic disease after 28.9+/-9.8 months.
  • Application of radiation therapy was associated with a better survival (p=0.003).
  • Complications related to the surgical intervention were recorded in 2/27 patients, complications related to radiation therapy occurred in 6/15 patients.
  • In cases with involvement of neurovascular structures, preoperative down-staging with radio or chemo-therapy may prevent amputation.
  • [MeSH-major] Leg. Limb Salvage / methods. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Factors. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17174515.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Lans TE, Grünhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol; 2005 May;12(5):406-11
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
  • BACKGROUND: Recurrent extremity soft tissue sarcoma (STS) in a previously operated and irradiated area can usually be managed only by amputation.
  • Because radiotherapy is known to destroy vasculature, we wanted to evaluate retrospectively whether the outcome of ILP in patients with radiotherapy for their primary tumor nonetheless showed a benefit from TNF treatment.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Limb Salvage / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Combined Modality Therapy. Female. Humans. Leg. Male. Middle Aged

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915375.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


11. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


12. Sobel E, Giorgini R, Oropeza R, Bapat K, Richardson H: Limb salvage in recurrent synovial sarcoma of the right ankle and lower leg. J Am Podiatr Med Assoc; 2002 Feb;92(2):90-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage in recurrent synovial sarcoma of the right ankle and lower leg.
  • Synovial sarcoma of the extremities represents 7% of all soft-tissue sarcomas.
  • This article presents the case of a patient who was treated for a synovial sarcoma of the lateral aspect of the distal lower leg extending to the ankle and involving the fibular bone.
  • The patient underwent a wide excision of the tumor, including the fibular bone, followed by radiation and chemotherapy, rather than undergo an amputation of the right leg.
  • [MeSH-major] Bone Neoplasms / therapy. Limb Salvage / methods. Neoplasm Recurrence, Local / therapy. Sarcoma, Synovial / surgery
  • [MeSH-minor] Adult. Ankle. Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Leg. Osteotomy / methods. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11847260.001).
  • [ISSN] 8750-7315
  • [Journal-full-title] Journal of the American Podiatric Medical Association
  • [ISO-abbreviation] J Am Podiatr Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Dodd LG, Major N, Brigman B: Malignant giant cell tumor of soft parts. Skeletal Radiol; 2004 May;33(5):295-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant giant cell tumor of soft parts.
  • Giant cell tumor of soft parts (GCTSP) is an extremely rare lesion with an unpredictable behavior.
  • The patient presented with a fungating skin and soft tissue mass and concurrent pulmonary nodules.
  • [MeSH-major] Giant Cell Tumors / pathology. Leg / pathology. Lung Neoplasms / diagnosis. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Diagnosis, Differential. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):736-47 [7226022.001]
  • [Cites] Cancer. 1972 Jun;29(6):1518-29 [5031245.001]
  • [Cites] Am J Dermatopathol. 1989 Jun;11(3):197-201 [2658646.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] Am J Surg. 1978 Jul;136(1):102-6 [277073.001]
  • [Cites] Cancer. 1977 Jul;40(1):244-53 [195704.001]
  • (PMID = 14997349.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Nizza D, Simoneaux SF: Blastic plasmacytoid dendritic cell neoplasm presenting as a subcutaneous mass in an 8-year-old boy. Pediatr Radiol; 2010 Dec;40 Suppl 1:S40-2
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blastic plasmacytoid dendritic cell neoplasm presenting as a subcutaneous mass in an 8-year-old boy.
  • Blastic plasmacytoid dendritic cell neoplasm (also referred to as CD4+/CD56+ hematodermic neoplasm) is a rare hematological malignancy typically seen in older adults.
  • The disease presents with nonspecific cutaneous lesions and advances toward a fatal leukemic phase despite an often favorable initial response to chemotherapy.
  • We report a case of histopathologically proven blastic plasmacytoid dendritic cell neoplasm arising in an otherwise healthy and asymptomatic 8-year-old boy who noticed a painless mass within the subcutaneous tissues below the left calf.
  • [MeSH-major] Dendritic Cells / diagnostic imaging. Dendritic Cells / pathology. Diagnostic Imaging / methods. Plasmacytoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Humans. Leg / diagnostic imaging. Leg / pathology. Male. Radionuclide Imaging

  • Genetic Alliance. consumer health - Blastic Plasmacytoid Dendritic Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2009;41(3):223-8 [19291533.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):981-9 [17018683.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):958-63 [15937306.001]
  • [Cites] Blood. 2009 Jul 30;114(5):937-51 [19357394.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):149-51 [17227117.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1097-108 [15205205.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):637-46 [13130309.001]
  • [Cites] Haematologica. 2006 Dec;91(12 Suppl):ECR48 [17194654.001]
  • (PMID = 20552185.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, Fang K, Zhong D, Ling Q: Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol; 2009 Jan;89(1):113-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature.
  • We report a case of a 58-year-old man who presented with a rapidly growing proliferative lesion on the left lower limb, clinically resembling a soft tissue sarcoma 3 years after renal allograft.
  • There was no evidence of systemic involvement on bone marrow needle aspiration and computed tomography (CT) scans of the chest and abdomen.
  • The lesion turned out to be primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas by skin biopsy.
  • Immunosuppression reduction, chemotherapy with CHOP regimen and local radiotherapy induced complete remission of the tumor.
  • [MeSH-minor] Humans. Leg / pathology. Male. Middle Aged. Neoplasm Invasiveness. Remission Induction / methods. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Pediatr Transplant. 2005 Oct;9(5):622-6 [16176420.001]
  • [Cites] J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83 [16703222.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1140-6 [15381556.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Clin Transplant. 2005 Oct;19(5):668-73 [16146560.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):874-80 [16225594.001]
  • [Cites] Transplant Proc. 2006 Mar;38(2):641-5 [16549195.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1071-3 [17524894.001]
  • [Cites] Clin Transplant. 2005 Jun;19(3):327-34 [15877793.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):574-80 [11939732.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1144-50 [17875875.001]
  • [Cites] Transplantation. 2005 Sep 15;80(5):595-9 [16177631.001]
  • [Cites] Transplant Proc. 2006 Oct;38(8):2448-50 [17097963.001]
  • [Cites] Blood. 2002 Feb 1;99(3):800-5 [11806979.001]
  • [Cites] J Cutan Pathol. 2005 Nov;32(10):647-74 [16293178.001]
  • [Cites] Transplantation. 2006 Mar 27;81(6):888-95 [16570013.001]
  • [Cites] Arch Dermatol. 2005 Sep;141(9):1139-45 [16172311.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1065-70 [16957512.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):193-7 [16041263.001]
  • (PMID = 19109733.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


16. Miliziano JS, Bradley YC: Soft tissue metastases and lung cancer recurrence detected by Tc-99m depreotide scintigraphy. Clin Nucl Med; 2002 Jun;27(6):410-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue metastases and lung cancer recurrence detected by Tc-99m depreotide scintigraphy.
  • A Tc-99m depreotide scan, however, led to a noninvasive diagnosis of lung cancer recurrence with metastases, and it directed a noninvasive tissue diagnosis.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Lung Neoplasms / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Soft Tissue Neoplasms / radionuclide imaging. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Female. Humans. Leg / radionuclide imaging. Middle Aged. Organotechnetium Compounds. Radiopharmaceuticals. Scapula / radionuclide imaging. Somatostatin / analogs & derivatives. Technetium Tc 99m Medronate. Thoracic Vertebrae / radionuclide imaging. Whole-Body Counting

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12045431.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 51110-01-1 / Somatostatin; 9M48M2SF02 / technetium Tc 99m depreotide; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


17. Grünhagen DJ, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM: Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol; 2005 Jun;12(6):473-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg.
  • BACKGROUND: Treatment for extremity soft tissue sarcoma (STS) has shifted in recent years from amputation to local wide excision combined with irradiation.
  • To avoid amputations, isolated limb perfusion (ILP) with tumor necrosis factor and melphalan is an attractive treatment option for patients with multiple extremity sarcomas.
  • All ILPs were performed under mild hyperthermic conditions by using 1 to 4 mg of tumor necrosis factor and 10 to 13 mg/L of limb volume for leg and arm perfusions, respectively.
  • The toxicity of the procedure was mild to moderate in almost all cases; no treatment-related amputation had to be performed.
  • The time to local recurrence was 29 months and differed significantly between multiple primary and multiple recurrent STS.
  • Because this treatment option provides excellent local control, it should be considered before an amputation is planned.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Limb Salvage. Neoplasms, Second Primary / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amputation. Arm / pathology. Disease Progression. Female. Humans. Hyperthermia, Induced. Leg / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864484.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Mentzel T, Katenkamp D: Sclerosing, pseudovascular rhabdomyosarcoma in adults. Clinicopathological and immunohistochemical analysis of three cases. Virchows Arch; 2000 Apr;436(4):305-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma in adults represents a rare soft tissue neoplasm which is seen most frequently in its pleomorphic subtype in this age group.
  • One developed a deep-seated soft tissue mass in the left lower leg, and one, a tumour of the left upper jaw.
  • In one patient a bone tumour in the proximal body of the sacrum without extension into soft tissues was seen.
  • The patients were treated by wide excision, piecemeal excision and incomplete excision in one case each; additional radiotherapy was performed in all three cases, and chemotherapy in two patients.
  • In one patient multiple pulmonary metastases were noted, which showed progression despite systemic chemotherapy.
  • [MeSH-major] Rhabdomyosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10834531.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


19. Ramirez RN, Otsuka NY, Apel DM, Bowen RE: Desmoid tumor in the pediatric population: a report of two cases. J Pediatr Orthop B; 2009 May;18(3):141-4
Genetic Alliance. consumer health - Desmoid Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They tend to extensively infiltrate surrounding tissues, complicating the treatment.
  • The first patient had tumor that necessitated removal of most of the anterior compartment of his leg.
  • The tumor in the second case was intimately involved with neurovascular structures and, therefore adjuvant treatment including chemotherapy and repeat surgery was necessary.
  • [MeSH-major] Fibromatosis, Aggressive / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Infant. Leg / surgery. Male. Neoplasm Recurrence, Local. Tendon Transfer. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322113.001).
  • [ISSN] 1473-5865
  • [Journal-full-title] Journal of pediatric orthopedics. Part B
  • [ISO-abbreviation] J Pediatr Orthop B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Grünhagen DJ, de Wilt JH, Verhoef C, van Geel AN, Eggermont AM: TNF-based isolated limb perfusion in unresectable extremity desmoid tumours. Eur J Surg Oncol; 2005 Oct;31(8):912-6
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoid tumours are soft tissue sarcomas with local aggressive behaviour and a high rate of local recurrence after treatment.
  • As isolated limb perfusion (ILP) with TNF and melphalan has proven to be extremely effective in the treatment of soft tissue sarcoma, we studied its potential in locally advanced extremity desmoid tumours.
  • Local surgical therapy with preservation of limb function was impossible in all patients due to large or multifocal tumours, multiple recurrences or extensive previous treatment.
  • Perfusions were performed with 4-3mg TNF and 10-13 mg/l limb volume melphalan form leg and arm perfusions, respectively.
  • Local control was obtained after 10/12 ILPs and in the other two patients through repeat ILP and systemic chemotherapy, thus leading to an overall local control rate of 100%.
  • CONCLUSION: ILP is a very effective treatment option in the multimodality treatment of limb desmoid tumours.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Dermoid Cyst / drug therapy. Lower Extremity / pathology. Melphalan / administration & dosage. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage. Upper Extremity / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Female. Humans. Limb Salvage. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Prospective Studies. Remission Induction. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098709.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


21. Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM: Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol; 2000 Nov 15;18(22):3794-803
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Synovial sarcoma (SS) is a common soft tissue sarcoma (STS) with a propensity for young adults and notable sensitivity to chemotherapy (CT).
  • Age greater than 20 years at diagnosis implied worse prognosis.
  • Therapeutic CT was administered to 55 patients.
  • SS is often chemosensitive, and given its poor prognosis, multicenter trials of adjuvant therapy are warranted.
  • [MeSH-major] Sarcoma, Synovial / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Databases, Factual. Disease-Free Survival. Female. Humans. Leg. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078492.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Dürr HR, Pellengahr C, Nerlich A, Baur A, Maier M, Jansson V: Stewart-Treves syndrome as a rare complication of a hereditary lymphedema. Vasa; 2004 Feb;33(1):42-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite of chemotherapy, local hyperthermia and later amputation of the extremity the patient died of progressive disease due to pulmonary metastasis.
  • In respect to this case, the different therapeutic concepts, as reported in the literature, and their results are presented and discussed.
  • [MeSH-major] Leg. Lymphangiosarcoma / diagnosis. Lymphedema / complications. Lymphedema / genetics. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Amputation. Antigens, CD31 / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Genes, Dominant. Genetic Predisposition to Disease / genetics. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Skin / pathology. Syndrome

  • Genetic Alliance. consumer health - Lymphedema.
  • Genetic Alliance. consumer health - Stewart Treves syndrome.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15061047.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD31
  •  go-up   go-down


23. Pritsch T, Bickels J, Winberg T, Malawer MM: Popliteal sarcomas: presentation, prognosis, and limb salvage. Clin Orthop Relat Res; 2007 Feb;455:225-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas of the popliteal fossa are rare diseases.
  • Their prognosis is inferior to intracompartmental extremity soft tissue sarcomas.
  • Seventeen patients were treated with radiotherapy and 10 patients received chemotherapy.
  • Soft tissue sarcomas of the popliteal fossa have an atypical presentation.
  • [MeSH-major] Leg. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Limb Salvage. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957647.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Noorda EM, Vrouenraets BC, Nieweg OE, Van Coevorden F, Kroon BB: Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol; 2004 Sep;11(9):837-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Following the principles of Evidence-Based Medicine, we reviewed the best available evidence for isolated limb perfusion (ILP) for melanoma and soft tissue sarcoma (STS) of the limb.
  • Therapeutic M-ILP, with or without tumor-necrosis factor alpha and interferon gamma (T(I)M-ILP), seems indicated in unresectable melanoma (level 3 to 4 evidence).
  • A comparison of level 3 to 4 studies on ILP and other neoadjuvant treatment modalities for unresectable STS shows that ILP results in the highest limb salvage rate with the lowest complication rate.
  • ILP seems the most effective limb sparing, neoadjuvant treatment modality when compared with other neoadjuvant treatment options for unresectable STS of the limb (level 3 to 4 evidence), although randomized studies are lacking.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Arm. Evidence-Based Medicine. Humans. Leg. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313738.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


25. Bula P, Bula-Sternberg J, Wollina U, Haroske G, Bonnaire F: [Marjolin's ulcer: malignant transformation of a crural ulcer due to posttraumatic chronic osteomyelitis]. Unfallchirurg; 2010 Feb;113(2):149-54
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of an 81-year-old female patient who developed a squamous cell carcinoma in a long-lasting therapy-resistant crural ulcer of the lower leg due to posttraumatic chronic osteomyelitis.
  • Eventually the lower leg had to be amputated because of massive destruction of soft tissue and the tibia bone.
  • [MeSH-major] Amputation. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Transformation, Neoplastic / pathology. Leg Injuries / pathology. Leg Injuries / surgery. Leg Ulcer / pathology. Leg Ulcer / surgery. Osteomyelitis / pathology. Osteomyelitis / surgery. Pseudomonas Infections / pathology. Pseudomonas Infections / surgery. Pseudomonas aeruginosa. Skin Ulcer / pathology. Tibia / surgery. Wounds, Penetrating / pathology. Wounds, Penetrating / surgery
  • [MeSH-minor] Aged, 80 and over. Artificial Limbs. Chronic Disease. Disease Progression. Drug Resistance, Bacterial. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Skin / pathology

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1999 May;(362):181-9 [10335297.001]
  • [Cites] J South Orthop Assoc. 1999 Fall;8(3):181-7 [12132863.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jan;63(1):62-4 [9064114.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Jul;6(7):569-72 [18248496.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):571-4 [7577586.001]
  • [Cites] Acta Orthop Belg. 1993;59(4):327-32 [8116362.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Aug;21(7):935-41 [17659003.001]
  • [Cites] Adv Dermatol. 1987;2:19-46 [3079255.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Med J Aust. 1996 Jun 17;164(12):718-20 [8668077.001]
  • [Cites] South Med J. 2005 Oct;98(10):1053 [16295826.001]
  • [Cites] Dermatol Online J. 2007 May 01;13(2):27 [17498446.001]
  • [Cites] Indian J Cancer. 1996 Sep;33(3):139-44 [9055488.001]
  • [Cites] J Burn Care Rehabil. 1990 Sep-Oct;11(5):460-9 [2246317.001]
  • [Cites] Int J Dermatol. 1991 Jan;30(1):58-61 [1993569.001]
  • [Cites] Int Orthop. 2001;25(6):389-91 [11820449.001]
  • [Cites] J Foot Surg. 1981 Fall;20(3):136-41 [7276451.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jan;72(1):12-8 [2295659.001]
  • [Cites] J Clin Pathol. 1963 Nov;16:573-80 [14076377.001]
  • [Cites] Ann Dermatol Venereol. 1993;120(10):675-8 [8161096.001]
  • [Cites] Orthop Rev. 1991 Jul;20(7):625-8 [1945509.001]
  • [Cites] Ann Surg. 1981 May;193(5):598-605 [7235765.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Feb;20(2):141-3 [8113507.001]
  • [Cites] J Mal Vasc. 2001 Apr;26(2):85-91 [11319413.001]
  • [Cites] Clin Orthop Relat Res. 1985 Sep;(198):264-7 [4028559.001]
  • [Cites] Dermatol Surg. 1996 Dec;22(12):1015-8 [9078313.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2007 Feb;93(1):63-71 [17389826.001]
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):331-7 [11465774.001]
  • [Cites] Arch Phys Med Rehabil. 1986 Nov;67(11):831-3 [3778183.001]
  • (PMID = 19859679.001).
  • [ISSN] 1433-044X
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. McGrory JE, Rock MG, Nascimento AG, Oliveira AM: Extraskeletal myxoid chondrosarcoma. Clin Orthop Relat Res; 2001 Jan;(382):185-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of the primary site included wide excision or amputation in 13 patients and marginal or intralesional resections with radiation in three patients.
  • Local recurrence developed in four, and metastases developed in six of 13 patients presenting with localized disease.
  • Of six patients who received chemotherapy for systemic disease, four had disease progression and died, and two had a response to chemotherapy (one partial, one complete).
  • The current series suggests that extraskeletal myxoid chondrosarcoma is an intermediate-grade neoplasm with a tendency toward recurrence and metastasis.
  • More effective therapy for systemic disease is needed.
  • [MeSH-major] Chondrosarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Amputation. Chemotherapy, Adjuvant. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Leg / surgery. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11153986.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Altmann S, Lenz-Scharf O, Schneider W: [Therapeutic options for aggressive fibromatosis]. Handchir Mikrochir Plast Chir; 2008 Apr;40(2):88-93
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic options for aggressive fibromatosis].
  • INTRODUCTION: Aggressive fibromatosis, e.g., desmoid tumour, is a rare neoplasm of the connective tissue with local infiltrative growth.
  • Because of the high recurrence rates and destruction of the surrounding tissue, these tumours are classified as semi-malignant.
  • Radical surgical treatment with tumour excision accompanied by radiotherapy is the current standard therapy that can be supplemented by pharmacological treatment in a few cases.
  • PATIENTS AND METHOD: We report on 9 patients (5 males and 4 females) with surgical therapy for aggressive fibromatosis.
  • The neoplasm was located on the extremities in 7 cases (4 x upper extremity, 3 x lower extremity), one tumour was situated in the chin and one in the rectus abdominis muscle.
  • In these cases, an adjuvant radiotherapy with 25 x 2 Gy was started postoperatively after the accomplished wound healing.
  • Treatment with chemotherapeutic agents was not necessary.
  • DISCUSSION: Aggressive fibromatosis is a semimalignant neoplasm of the connective tissue with an extremely high recurrence rate.
  • Therapy of choice is the radical surgical resection.
  • Pharmacological treatment should be considered for patients with unsuccessful local therapy.
  • [MeSH-major] Fibromatosis, Aggressive / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Arm. Chin. Female. Follow-Up Studies. Humans. Leg. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Rectus Abdominis. Surgical Flaps. Time Factors

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437666.001).
  • [ISSN] 0722-1819
  • [Journal-full-title] Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft für Mikrochirurgie der Peripheren Nerven und Gefässe : Organ der Vereinigung der Deutschen Plastischen Chirurgen
  • [ISO-abbreviation] Handchir Mikrochir Plast Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Hohenberger P, Tunn PU: Isolated limb perfusion with rhTNF-alpha and melphalan for locally recurrent childhood synovial sarcoma of the limb. J Pediatr Hematol Oncol; 2003 Nov;25(11):905-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six weeks later, the former tumor bed and irradiation field was excised together with myocutaneous flap reconstruction for soft tissue coverage.
  • Six months after completion of treatment, near-perfect limb function was determined by general clinical assessment and validated scoring systems.
  • ILP, an accepted technique in treating adult extremity sarcoma, might also be of value in children as a means of limb-saving therapy.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melphalan / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Sarcoma, Synovial / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adolescent. Child. Female. Humans. Leg. Male. Recombinant Proteins / administration & dosage

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14608203.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down






Advertisement